Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease – a randomized, open-label, multicenter phase II trial

BACKGROUND: Recently, the combination of the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab with first-line chemotherapy has demonstrated to improve outcome for patients with advanced small cell lung cancer (SCLC), leading to approval of this regimen. At the same time, accumulating (pre-)c...

Descripción completa

Detalles Bibliográficos
Autores principales: Bozorgmehr, Farastuk, Christopoulos, Petros, Chung, Inn, Cvetkovic, Jelena, Feißt, Manuel, Krisam, Johannes, Schneider, Marc A., Heußel, Claus Peter, Kreuter, Michael, Müller, Daniel W., Thomas, Michael, Rieken, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509547/
https://www.ncbi.nlm.nih.gov/pubmed/36153496
http://dx.doi.org/10.1186/s12885-022-10074-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509547/
https://www.ncbi.nlm.nih.gov/pubmed/36153496
http://dx.doi.org/10.1186/s12885-022-10074-9

Ejemplares similares